PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
- First Posted Date
- 2006-01-19
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9779
- Registration Number
- NCT00279448
- Locations
- π«π·
Pfizer Investigational Site, Vannes, France
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT00277810
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT00277238
- Locations
- πΊπΈ
Pfizer Investigational Site, Richmond, Virginia, United States
A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)
Phase 2
Completed
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2008-11-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 262
- Registration Number
- NCT00275197
- Locations
- π·πΊ
Pfizer Investigational Site, St. Petersburg, Russian Federation
A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00272961
- Locations
- πΊπΈ
Pfizer Investigational Site, Seattle, Washington, United States
A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses
Phase 2
Completed
- Conditions
- Impotence
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2006-08-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00273416
- Locations
- π¬π§
Pfizer Investigational Site, Belfast, Northern Ireland, United Kingdom
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Phase 2
Completed
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2011-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 317
- Registration Number
- NCT00267748
- Locations
- πΊπΈ
Pfizer Investigational Site, Madison, Wisconsin, United States
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
Phase 3
Terminated
- Conditions
- HyperlipidemiaDyslipidemiaHypercholesterolemia
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT00267280
- Locations
- πΊπΈ
Pfizer Investigational Site, Tacoma, Washington, United States
A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
Phase 3
Terminated
- Conditions
- HyperlipidemiaDyslipidemia
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1784
- Registration Number
- NCT00267267
- Locations
- πΊπΈ
Pfizer Investigational Site, Spokane, Washington, United States
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.
Phase 3
Completed
- Conditions
- HyperlipidemiaDyslipidemiaHypercholesterolemia
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2007-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 640
- Registration Number
- NCT00267254
- Locations
- πΊπΈ
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
Β© Copyright 2025. All Rights Reserved by MedPath